176 related articles for article (PubMed ID: 20466871)
1. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
[TBL] [Abstract][Full Text] [Related]
2. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
[TBL] [Abstract][Full Text] [Related]
3. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
[TBL] [Abstract][Full Text] [Related]
5. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Eckermann G; Lahu G; Nassr N; Bethke TD
J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
[TBL] [Abstract][Full Text] [Related]
6. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R
J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
[TBL] [Abstract][Full Text] [Related]
7. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
8. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
[TBL] [Abstract][Full Text] [Related]
10. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K
J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786
[TBL] [Abstract][Full Text] [Related]
11. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
14. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
de Mey C; Nassr N; Lahu G
BMC Clin Pharmacol; 2011 Jun; 11():7. PubMed ID: 21631929
[TBL] [Abstract][Full Text] [Related]
15. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Lahu G; Facius A
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):832-6. PubMed ID: 24152603
[TBL] [Abstract][Full Text] [Related]
16. Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.
Nassr N; Huennemeyer A; Herzog R; von Richter O; Hermann R; Koch M; Duffy K; Zech K; Lahu G
Br J Clin Pharmacol; 2009 Oct; 68(4):580-7. PubMed ID: 19843061
[TBL] [Abstract][Full Text] [Related]
17. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
[TBL] [Abstract][Full Text] [Related]
18. Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.
Nassr N; Lahu G; von Richter O; Reutter F; Knoerzer D; Zech K; Erb KA; Schug B; Blume H; Hermann R
Br J Clin Pharmacol; 2007 Mar; 63(3):365-70. PubMed ID: 16981901
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
[TBL] [Abstract][Full Text] [Related]
20. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.
Bethke TD; Böhmer GM; Hermann R; Hauns B; Fux R; Mörike K; David M; Knoerzer D; Wurst W; Gleiter CH
J Clin Pharmacol; 2007 Jan; 47(1):26-36. PubMed ID: 17192499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
